Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01751984 · ClinicalTrials.gov registry record · Phase 2
A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance
A Phase 2 study, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT01751984 is a Phase 2 study that has completed, run by Esperion Therapeutics. The registered enrollment target is 56 participants.
The verdict
NCT01751984, a Phase 2 study, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study will assess the Low-Density Lipoprotein-Cholesterol (LDL-C) lowering efficacy and safety of ETC-1002 versus placebo in participants with hypercholesterolemia and a history of statin intolerance.
Interventions
- DRUG Placebo
- DRUG ETC-1002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2012-10-04 |
| Est. Completion | 2013-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01751984
The ClinicalTrials.gov registry entry for NCT01751984 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Esperion Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01751984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01751984 about?
NCT01751984 is a clinical study titled "A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance". This study will assess the Low-Density Lipoprotein-Cholesterol (LDL-C) lowering efficacy and safety of ETC-1002 versus placebo in participants with hypercholesterolemia and a history of statin intolerance.
What is the current status of trial NCT01751984?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2012-10-04. Estimated completion is 2013-05-01.
What interventions are being tested in trial NCT01751984?
The interventions under investigation include: Placebo (DRUG), ETC-1002 (DRUG).
Who is sponsoring clinical trial NCT01751984?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.